[1] |
DE LA FUENTE-MANCERA JC, FORADO-BENTAR I, FARRERO M. Management of long-term cardiovascular risk factors post organ transplant[J]. Curr Opin Organ Transplant, 2022, 27(1): 29-35. DOI: 10.1097/MOT.0000000000000950.
|
[2] |
SHARIF A. Prevention of post-transplantation diabetes: small steps, big opportunities[J]. J Am Soc Nephrol, 2021, 32(8): 1833-1834. DOI: 10.1681/ASN.2021060777.
|
[3] |
WANG Q, WU J, WANG X, et al. Risk factors of new-onset diabetes after renal transplantation and prognostic analysis[J]. Altern Ther Health Med, 2023, 29(2): 230-235.
|
[4] |
中国康复医学会器官移植康复专业委员会. 成人实体器官移植后糖尿病管理专家共识[J]. 器官移植, 2023, 14(5): 623-642. DOI: 10.3969/j.issn.1674-7445.2023110.Organ Transplantation and Rehabilitation Committee of Chinese Medical Association of Rehabilitation. Expert consensus on diabetes mellitus after solid organ transplantation in adults[J]. Organ Transplant, 2023, 14(5): 623-642. DOI: 10.3969/j.issn.1674-7445.2023110.
|
[5] |
HE J, YANG M, QUAN X, et al. Microbial and metabolic features in renal transplant recipients with post-transplantation diabetes mellitus[J]. Int J Urol, 2023, 30(6): 504-513. DOI: 10.1111/iju.15158.
|
[6] |
陈荣鑫, 赖兴强, 张磊, 等. 肾移植受者发生移植后糖尿病的危险因素分析及预测模型的构建[J]. 器官移植, 2021, 12(3): 329-335. DOI: 10.3969/j.issn.1674-7445.2021.03.012.CHEN RX, LAI XQ, ZHANG L, et al. Analysis of risk factors and establishment of prediction model for post transplantation diabetes mellitus in renal transplant recipients[J]. Organ Transplant, 2021, 12(3): 329-335. DOI: 10.3969/j.issn.1674-7445.2021.03.012.
|
[7] |
WANG L, HUANG J, LI Y, et al. Postoperative fasting plasma glucose and family history diabetes mellitus can predict post-transplantation diabetes mellitus in kidney transplant recipients[J]. Endocrine, 2023, 81(1): 58-66. DOI: 10.1007/s12020-023-03374-y.
|
[8] |
SHARIF A, HECKING M, DE VRIES AP, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions[J]. Am J Transplant, 2014, 14(9): 1992-2000. DOI: 10.1111/ajt.12850.
|
[9] |
LIN Y, MOK M, HARRISON J, et al. Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: a systematic review[J]. Transplant Rev (Orlando), 2023, 37(1): 100729. DOI: 10.1016/j.trre.2022.100729.
|
[10] |
HARREITER J, RODEN M. Diabetes mellitus: definition, classification, diagnosis, screening and prevention (Update 2023)[J]. Wien Klin Wochenschr, 2023, 135(Suppl 1): 7-17. DOI: 10.1007/s00508-022-02122-y.
|
[11] |
HECKING M, SHARIF A, ELLER K, et al. Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics[J]. Transpl Int, 2021, 34(1): 27-48. DOI: 10.1111/tri.13783.
|
[12] |
CHAITOU AR, VALMIKI S, VALMIKI M, et al. New-onset diabetes mellitus (NODM) after liver transplantation (lt): the ultimate non-diabetogenic immunosuppressive therapy[J]. Cureus, 2022, 14(3): e23635. DOI: 10.7759/cureus.23635.
|
[13] |
JENSSEN T, HARTMANN A. Post-transplant diabetes mellitus in patients with solid organ transplants[J]. Nat Rev Endocrinol, 2019, 15(3): 172-188. DOI: 10.1038/s41574-018-0137-7.
|
[14] |
PAUCHET A, SCHWOTZER N, LAMINE F, et al. Post-transplantation diabetes in kidney transplant: from the diabetologist point of view[J]. Rev Med Suisse, 2020, 16(697): 1200-1205.
|
[15] |
SHIVASWAMY V, BOERNER B, LARSEN J. Post-Transplant diabetes mellitus: causes, treatment, and impact on outcomes[J]. Endocr Rev, 2016, 37(1): 37-61. DOI: 10.1210/er.2015-1084.
|
[16] |
ZHANG Z, SUN J, GUO M, et al. Progress of new-onset diabetes after liver and kidney transplantation[J]. Front Endocrinol (Lausanne), 2023, 14: 1091843. DOI: 10.3389/fendo.2023.1091843.
|
[17] |
REID L, BAXTER F, FORBES S. Effects of islet transplantation on microvascular and macrovascular complications in type 1 diabetes[J]. Diabet Med, 2021, 38(7): e14570. DOI: 10.1111/dme.14570.
|
[18] |
KIM NG, SHARMA A, SAAB S. Cardiovascular and metabolic disease in the liver transplant recipient[J]. Best Pract Res Clin Gastroenterol, 2020, 46/47: 101683. DOI: 10.1016/j.bpg.2020.101683.
|
[19] |
DE VRIES DK, LINDEMAN JH, RINGERS J, et al. Donor brain death predisposes human kidney grafts to a proinflammatory reaction after transplantation[J]. Am J Transplant, 2011, 11(5): 1064-1070. DOI: 10.1111/j.1600-6143.2011.03466.x.
|
[20] |
NAESENS M, LI L, YING L, et al. Expression of complement components differs between kidney allografts from living and deceased donors[J]. J Am Soc Nephrol, 2009, 20(8): 1839-1851. DOI: 10.1681/ASN.2008111145.
|
[21] |
ABDELAZIZ TS, ALI AY, FATTHY M. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in kidney transplant recipients with post-transplant diabetes mellitus (PTDM)- a systematic review and meta-analysis[J]. Curr Diabetes Rev, 2020, 16(6): 580-585. DOI: 10.2174/1573399815666190321144310.
|
[22] |
中华医学会器官移植学分会. 中国肝移植免疫抑制治疗与排斥反应诊疗规范(2019版)[J]. 器官移植, 2021, 12(1): 8-14,28. DOI: 10.3969/j.issn.1674-7445.2021.01.002.Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)[J]. Organ Transplant, 2021, 12(1): 8-14,28. DOI: 10.3969/j.issn.1674-7445.2021.01.002.
|
[23] |
张岑, 王文妍, 文力. 类固醇相关糖尿病风险防范及诊治[J]. 临床药物治疗杂志, 2023, 21(8): 18-21. DOI: 10.3969/j.issn.1672-3384.2023.08.004.ZHANG C, WANG WY, WEN L. Risk prevention and treatment of steroid-induced diabetes mellitus[J]. Clin Med J, 2023, 21(8): 18-21. DOI: 10.3969/j.issn.1672-3384.2023.08.004.
|
[24] |
WOODLE ES, FIRST MR, PIRSCH J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy[J]. Ann Surg, 2008, 248(4): 564-577. DOI: 10.1097/SLA.0b013e318187d1da.
|
[25] |
WEBSTER AC, WOODROFFE RC, TAYLOR RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data[J]. BMJ, 2005, 331(7520): 810. DOI: 10.1136/bmj.38569.471007.AE.
|
[26] |
NOGUEIRAS-ÁLVAREZ R, MORA-CUESTA VM, CIFRIÁN-MARTÍNEZ JM, et al. Calcineurin inhibitors' impact on cardiovascular and renal function, a descriptive study in lung transplant recipients from the North of Spain[J]. Sci Rep, 2022, 12(1): 21207. DOI: 10.1038/s41598-022-25445-2.
|
[27] |
WANG Z, JIANG Z, LU R, et al. Formulation strategies to provide oxygen-release to contrast local hypoxia for transplanted islets[J]. Eur J Pharm Biopharm, 2023, 187: 130-140. DOI: 10.1016/j.ejpb.2023.04.015.
|
[28] |
VAN LAECKE S, VAN BIESEN W, VERBEKE F, et al. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation[J]. Am J Transplant, 2009, 9(9): 2140-2149. DOI: 10.1111/j.1600-6143.2009.02752.x.
|
[29] |
LOMBARDI Y, FRANÇOIS H. Belatacept in kidney transplantation: what are the true benefits? a systematic review[J]. Front Med (Lausanne), 2022, 9: 942665. DOI: 10.3389/fmed.2022.942665.
|
[30] |
ARAKI M, FLECHNER SM, ISMAIL HR, et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs[J]. Transplantation, 2006, 81(3): 335-341. DOI: 10.1097/01.tp.0000195770.31960.18.
|
[31] |
CAMAYA I, DONNELLY S, O'BRIEN B. Targeting the PI3K/Akt signaling pathway in pancreatic β-cells to enhance their survival and function: an emerging therapeutic strategy for type 1 diabetes[J]. J Diabetes, 2022, 14(4): 247-260. DOI: 10.1111/1753-0407.13252.
|
[32] |
OTHMAN N, GHEITH O, AL-OTAIBI T, et al. Effect of structured diabetes education on diabetic angiopathies among kidney transplant recipients with posttransplant diabetes: kuwait experience[J]. Exp Clin Transplant, 2022, 20(Suppl 1): 46-54. DOI: 10.6002/ect.MESOT2021.O19.
|
[33] |
DELOS SANTOS RB, HAGOPIAN JC, CHEN L, et al. Sitagliptin versus placebo to reduce the incidence and severity of posttransplant diabetes mellitus after kidney transplantation-a single-center, randomized, double-blind controlled trial[J]. Transplantation, 2023, 107(5): 1180-1187. DOI: 10.1097/TP.0000000000004373.
|
[34] |
KATHIRVEL M, MALLICK S, SETHI P, et al. Randomized trial of steroid free immunosuppression with basiliximab induction in adult live donor liver transplantation (LDLT)[J]. HPB (Oxford), 2021, 23(5): 666-674. DOI: 10.1016/j.hpb.2020.09.012.
|
[35] |
尚梦月, 陈永忠, 保洁, 等. 慢性乙型肝炎合并代谢相关脂肪性肝病的临床及病理特点分析[J]. 中华肝脏病杂志, 2023, 31(2): 126-132. DOI: 10.3760/cma.j.cn501113- 20220701-00362.SHANG MY, CHEN YZ, BAO J, et al. Analysis of clinical and pathological features of chronic hepatitis B combined with metabolic-associated fatty liver disease[J]. Chin J Hepatol, 2023, 31(2): 126-132. DOI: 10.3760/cma.j.cn501113-20220701-00362.
|
[36] |
张绍丽, 曹毛毛, 杨帆, 等. 1990—2019年中国人群肝癌各病因疾病负担变化趋势分析[J]. 中华消化外科杂志, 2023, 22(1): 122-130. DOI: 10.3760/cma.j.cn115610- 20221112-00687.ZHANG SL, CAO MM, YANG F, et al. Analysis of the change trend of etiological burden of disease of liver cancer in the Chinese population from 1990 to 2019[J]. Chin J Dig Surg, 2023, 22(1): 122-130. DOI: 10.3760/cma.j.cn115610-20221112-00687.
|
[37] |
PISANO G, FRACANZANI AL, CACCAMO L, et al. Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study[J]. World J Gastroenterol, 2016, 22(40): 8869-8882. DOI: 10.3748/wjg.v22.i40.8869.
|
[38] |
PATIL DT, YERIAN LM. Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation[J]. Liver Transpl, 2012, 18(10): 1147-1153. DOI: 10.1002/lt.23499.
|
[39] |
ANDRADE AR, BITTENCOURT PL, CODES L, et al. New onset diabetes and non-alcoholic fatty liver disease after liver transplantation[J]. Ann Hepatol, 2017, 16(6): 932-940. DOI: 10.5604/01.3001.0010.5285.
|